Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus rating of “Buy” from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $108.75.

MNPR has been the subject of several analyst reports. BTIG Research raised their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group set a $105.00 price target on Monopar Therapeutics in a research report on Monday. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating and issued a $105.00 price objective on shares of Monopar Therapeutics in a research report on Monday.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $97.79 on Friday. The company has a market cap of $655.19 million, a P/E ratio of -51.47 and a beta of 1.46. The stock’s fifty day moving average price is $65.43 and its two-hundred day moving average price is $62.55. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. On average, analysts expect that Monopar Therapeutics will post -2.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets raised its position in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics during the fourth quarter valued at $65,000. JPMorgan Chase & Co. boosted its stake in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics during the second quarter worth about $80,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.